At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany, explains the rationale of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of pancreatic cancer with mutations in the BRCA genes, including the current status of the clinical development and future directions for research in this field.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement